Diamond Therapeutics
The promise of a new and better class of mental health therapies lies within the chemistry of psychedelic compounds. Our mission is to unlock it. We're developing safe, FDA, EMA and Health Canada approved therapies for neuropsychiatric conditions, starting with sub-perceptual psilocybin-based medicines that have the potential to deliver greater impact than current first-line treatments. Our first clinical program is focused on accessible psilocybin-based drugs that deliver rapid therapeutic outcomes without perceptual side effects. By eliminating the side effects, this intervention can be administered to a broad cohort of patients.
7-day free trial · no credit card
Verified contacts
5
available on Kipplo
LinkedIn employees
8
1 to 10 range
Open roles
—
no listings
Distinct roles
4
indexed titles
Tech stack
1
tools in use
Monthly traffic
32
organic / mo
Sign up free to see all 5 verified contacts at Diamond Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
5 contacts with verified email or phone · masked until revealed.
- JB
Judy Blumstock
Founder & CEO · Other
EmailPhone - GM
Grant McCutcheon
Chief Financial Officer · Finance & Accounting
EmailPhone - WH
William Hilson
Founding Investor & Advisor · Finance & Accounting
EmailPhone - WJ
William Jamie T.
Co-founder · General Business & Management
EmailPhone
Showing 4 of 5 verified contacts
Top roles at Diamond Therapeutics
4 distinct titles indexed · top 4 shown.
- 1chief financial officer
- 1co-founder
- 1founder & ceo
- 1founding investor & advisor
Sign up to unlock all 5 contacts at Diamond Therapeutics
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 5 verified contacts at Diamond Therapeutics
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.